Bejon P

Helminth infection and eosinophilia and the risk of Plasmodium falciparum malaria in 1- to 6-year-old children in a malaria endemic area.Bejon, P. Mwangi, T. W. Lowe, B. Peshu, N. Hill, A. V. Marsh, K.
PLoS Negl Trop Dis, (2008). 2:e164

Incorporating a quiz into informed consent processes: qualitative study of participants' reactions.Molyneux, S. Gikonyo, C. Marsh, V. Bejon, P.
Malar J, (2007). 6:145

Clearing asymptomatic parasitaemia increases the specificity of the definition of mild febrile malaria.Bejon, P. Mwangi, T. Lowe, B. Peshu, N. Hill, A. V. Marsh, K.
Vaccine, (2007). 25:8198-202

The induction and persistence of T cell IFN-gamma responses after vaccination or natural exposure is suppressed by Plasmodium falciparum.Bejon, P. Mwacharo, J. Kai, O. Todryk, S. Keating, S. Lowe, B. Lang, T. Mwangi, T. W. Gilbert, S. C. Peshu, N. Marsh, K. Hill, A. V.
J Immunol, (2007). 179:4193-201

Defining childhood severe falciparum malaria for intervention studies.Bejon, P. Berkley, J. A. Mwangi, T. Ogada, E. Mwangi, I. Maitland, K. Williams, T. Scott, J. A. English, M. Lowe, B. S. Peshu, N. Newton, C. R. Marsh, K.
PLoS Med, (2007). 4:e251

Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya.Bejon, P. Ogada, E. Mwangi, T. Milligan, P. Lang, T. Fegan, G. Gilbert, S. C. Peshu, N. Marsh, K. Hill, A. V.
PLoS One, (2007). 2:e707

A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya.Bejon, P. Mwacharo, J. Kai, O. Mwangi, T. Milligan, P. Todryk, S. Keating, S. Lang, T. Lowe, B. Gikonyo, C. Molyneux, C. Fegan, G. Gilbert, S. C. Peshu, N. Marsh, K. Hill, A. V.
PLoS Clin Trials, (2006). 1:e29

Early gamma interferon and interleukin-2 responses to vaccination predict the late resting memory in malaria-naive and malaria-exposed individuals.Bejon, P. Keating, S. Mwacharo, J. Kai, O. K. Dunachie, S. Walther, M. Berthoud, T. Lang, T. Epstein, J. Carucci, D. Moris, P. Cohen, J. Gilbert, S. C. Peshu, N. Marsh, K. Hill, A. V.
Infect Immun, (2006). 74:6331-8

Alternating vector immunizations encoding pre-erythrocytic malaria antigens enhance memory responses in a malaria endemic area.Bejon, P. Kai, O. K. Mwacharo, J. Keating, S. Lang, T. Gilbert, S. C. Peshu, N. Marsh, K. Hill, A. V.
Eur J Immunol, (2006). 36:2264-72

Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area.Bejon, P. Mwacharo, J. Kai, O. K. Todryk, S. Keating, S. Lang, T. Gilbert, S. C. Peshu, N. Marsh, K. Hill, A. V.
Vaccine, (2006). 24:4709-15

Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya.Bejon, P. Peshu, N. Gilbert, S. C. Lowe, B. S. Molyneux, C. S. Forsdyke, J. Lang, T. Hill, A. V. Marsh, K.
Clin Infect Dis, (2006). 42:1102-10

Invasive Gram-negative bacilli are frequently resistant to standard antibiotics for children admitted to hospital in Kilifi, Kenya.Bejon, P. Mwangi, I. Ngetsa, C. Mwarumba, S. Berkley, J. A. Lowe, B. S. Maitland, K. Marsh, K. English, M. Scott, J. A.
J Antimicrob Chemother, (2005). 56:232-5

B cell memory to 3 Plasmodium falciparum blood-stage antigens in a malaria-endemic area.Dorfman, J. R. Bejon, P. Ndungu, F. M. Langhorne, J. Kortok, M. M. Lowe, B. S. Mwangi, T. W. Williams, T. N. Marsh, K.
J Infect Dis, (2005). 191:1623-30

Malaria.Maitland, K. Bejon, P. Newton, C. R.
Curr Opin Infect Dis, (2003). 16:389-95